TrialThe oncologist2012

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

Bruno Coudert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.